Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec- tively. The management of immune related toxicities is keypoint for adequate use of these agents.